Novo Nordisk has cut listed prices for its Wegovy weight-loss drug by about 50% in parts of China as competition intensifies ahead of a key patent expiry on semaglutide in March. The move, reported by Bloomberg, is aimed at easing patient costs and protecting market share as new domestic obesity treatments and generics prepare to enter the market.